title: Use of erythropoietin in premature neonates: controversies and the future.
abstract: OBJECTIVE
  To review and evaluate current research on the use of recombinant human erythropoietin (rhEPO) for the treatment of anemia of prematurity (AOP).
  
  
  METHODS
  A MEDLINE search (1985-September 1994) was used to identify and retrieve pertinent data about erythropoietin's use in premature neonates. Bibliographies in the relevant literature and International Pharmacy Abstracts were reviewed as well.
  
  
  METHODS
  The authors extrapolated data from trials and other literature in which the entire paper or abstract was published. Because of the paucity of data on the use of rhEPO in neonates, all available literature was reviewed and cited, regardless of study methodology.
  
  
  RESULTS
  Most data support that rhEPO is efficacious in treating AOP. Until recently, the published investigations have included only small numbers of patients. Larger, multicenter, placebo-controlled trials suggest that infants weighing less than 1500 g benefit from rhEPO therapy. Questions remain concerning the rhEPO dose and nutrient requirements for optimal efficacy.
  
  
  CONCLUSIONS
  Published clinical trials that have examined the efficacy of rhEPO in the treatment of AOP vary considerably with regard to methodology, rhEPO dose, nutrient doses, and outcome measurement. At present, many questions remain to be answered including ascertaining rhEPO's long-term benefit versus cost/risk as well as its potential contribution to improving the care of the premature neonate.
authors.affiliation: School of Pharmacy, Robert C. Byrd Health Sciences Center of West Virginia University, Charleston 25304, USA.
authors.forename: T L
authors.initials: TL
authors.lastname: Wandstrat
authors.forename: B
authors.initials: B
authors.lastname: Kaplan
mesh_terms: D000751:Anemia, Neonatal / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D017850:Economics, Pharmaceutical; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin